NeuroFrontiers

Guest: Ashvini Keshavan, MRCP, PhD Very few patients in UK memory services receive an Alzheimer’s diagnosis supported by molecular testing, limiting timely access to emerging therapies. The ADAPT trial—which was funded by the Blood Biomarker Challenge, a multi-million-pound program supported by the Alzheimer's Society, Alzheimer's Research UK, and players of People's Postcode Lottery—aims to close this gap by evaluating the real-world integration of blood-based biomarkers into standard NHS memory care pathways. Join Dr. Ashvini Keshavan as she discusses how this approach may impact diagnostic accuracy, treatment access, and healthcare resource use across the UK. Dr. Keshavan is a Senior Clinical Research Fellow and Honorary Consultant Neurologist specializing in Alzheimer’s disease biomarkers at the University College London, and this topic was presented as a poster at the 2025 CTAD conference.

Guest: Sergio Baranzini, PhD In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Host: Jennifer Caudle, DO Guest: Katie Beadon, MD, MASc, FRCPC Multifocal motor neuropathy (MMN) is a chronic, immune-mediated motor neuropathy that can mimic other neuromuscular disorders1-3 and is one of the few motor neuron disorders that is treatable.4 However, disease severity correlates with the length of time a patient remains untreated, which is why early recognition and treatment initiation is essential for preserving long-term motor function.5-6 Joining Dr. Jennifer Caudle to discuss the diagnosis and management of MMN is Dr. Katie Beadon, Co-Director of St. Paul’s Hospital Immunotherapy in Neurology Clinic and an Assistant Clinical Professor at the University of British Columbia in Vancouver. References: Guimarães-Costa R, Bombelli F, Léger JM. Multifocal motor neuropathy. Presse Med. 2013;42(6 Pt 2):e217-24. doi:10.1016/j.lpm.2013.01.057 Beadon K, Guimarães-Costa R, Léger JM. Multifocal motor neuropathy. Curr Opin Neurol. 2018;31(5):559-564. doi:10.1097/WCO.0000000000000605 Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48-58. doi:10.1038/nrneurol.2011.175 Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry. 2020;91(2):140-148. doi:10.1136/jnnp-2019-321532 Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75(9):818-25. doi:10.1212/WNL.0b013e3181f0738e Van …

Host: Ryan Quigley A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Guest: Marisa McGinley, DO The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, including the BEAT-MS trial, with Dr. Marisa McGinley, a neurologist at the Cleveland Clinic.

Early symptoms of multiple sclerosis (MS) often present as clear, localized neurological changes lasting several days. However, many nonspecific complaints and common MRI findings can mimic MS, leading to misdiagnosis and unnecessary treatment. Dr. Jonathan Howard, an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital, reviews hallmark symptom patterns, explains how to differentiate benign MRI changes from true disease, and underscores the importance of thorough history-taking, neurological exams, and targeted testing to ensure accurate diagnosis and optimal patient care.

Since 2010, the landscape of multiple sclerosis care has transformed to encompass a variety of medications, each having unique benefits, risks, and side effect profiles. Dr. Jonathan Howard discusses how to match treatment strength to disease severity and balance patient risk tolerance with evolving therapeutic options, from long-standing injectables to infusions and oral therapies. Dr. Howard is an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital in New York.

Guest: David Gate, PhD Patients with Alzheimer's disease—especially APOE4 carriers—show distinct epigenetic immune alterations that may influence disease progression, treatment response, and side effect risk. In this episode, Dr. David Gate, an Assistant Professor of Behavioral Neurology at Northwestern University, dives into his research on this subject and explains how chromatin accessibility in proinflammatory genes and T-cell receptor changes link to neurological pathology.

Guest: Marisa McGinley, DO Multiple sclerosis (MS) treatment has transformed dramatically, with a wide range of high-efficacy options currently available. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, explores how advancements in drug availability, administration methods, and efficacy are reshaping care, with a focus on sequencing strategies and the growing movement toward early, aggressive treatment. Learn how to integrate patient preferences, comorbidities, and shared decision-making into personalized therapy plans.

Guest: Marisa McGinley, DO Multiple sclerosis (MS) presents with far more than just mobility issues—fatigue, spasticity, bladder and bowel dysfunction, cognitive changes, and mood disorders are frequently underrecognized but deeply impactful. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, explains how to identify subtle clinical changes, utilize patient-reported outcomes, and engage in proactive symptom discussions that support timely interventions.

Guest: Marisa McGinley, DO Multiple sclerosis (MS) presents a diverse range of symptoms that require coordinated, expert care. Dr. Marisa McGinley, a neurologist at the Cleveland Clinic, provides practical strategies for neurologists to serve as the central point of contact for patients with MS, initiate targeted treatments, and engage a variety of specialty teams in collaborative management.

Guest: John Golden Host: Michael Greenberg, MD Neuro-responsive EEG headphones are helping healthcare professionals combat burnout by promoting calm, focus, and resilience. Backed by neuroscience and real-time brain monitoring, this personalized technology blends music and neurofeedback to optimize mental states and reduce stress. Hear from Vital Neuro CEO John Golden as he joins Dr. Michael Greenberg to discuss this device's impact in clinical workflows, from pre-op anxiety management to enhanced physician well-being.

Guest: John Golden Guest: Michael Greenberg, MD EEG-guided headphones from Vital Neuro present a new frontier in anxiety management through personalized, real-time neurofeedback and music therapy. Dr. Michael Greenberg speaks with Vital Neuro CEO John Golden about the science behind these devices, their effectiveness in reducing anxiety symptoms, and how they can integrate into daily life.

Guest: Riley Bove, MD, MMSc Many patients with multiple sclerosis (MS) experience neurogenic bladder symptoms—ranging from urgency and incontinence to retention and infection risk—but these issues are often underprioritized in care. Based on recent research, remote, commercially available bladder monitoring tools can help address this unmet need and uncover day-to-day fluctuations in bladder function. To learn more about this research, tune in to hear from Dr. Riley Bove. Not only is Dr. Bove a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences, but she also presented a session on this exact topic at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting.

Guest: John A. Morren, MD, FAAN, FAANEM The symptom variability, prolonged asymptomatic periods, and inconsistent presentations of generalized myasthenia gravis (gMG) often lead to significant diagnostic delays and misdiagnoses. Based on recent studies, these delays then correlate with increased disease severity, longer time to symptom control, and worsened quality of life. Here to help uncover the hidden toll of diagnostic delays on patients with gMG is Dr. John Morren. He’s the Program Director of the Neuromuscular Medicine Fellowship at Cleveland Clinic and an Associate Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Guest: Riley Bove, MD, MMSc From pregnancy planning and postpartum relapse risk to the overlapping symptoms of menopause, women with multiple sclerosis (MS) face unique challenges throughout the reproductive lifespan. Here to share key takeaways from her session at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting that focused on how we can better care for these patients is Dr. Riley Bove, a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences.

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Emile Maamary Guest: Mark Elias For patients with who struggle with daily activities due to Parkinson's disease or essential tremor, treatment options are mostly limited to medication and invasive surgery. That's why Steadiwear co-founders Mark Elias and Emile Maamary developed an FDA-registered glove engineered to suppress hand tremors. Dr. Jerome Lisk sits down with Mr. Elias and Mr. Maamary to learn more about the device and its potential real-world impacts.

Guest: Rosaline Quinlivan As patients with Duchenne muscular dystrophy (DMD) transition from pediatric to adult care, they may encounter healthcare professionals—from primary care to emergency medicine—without prior experience managing their condition. Explore critical gaps in adult services for DMD and gain practical insights to help deliver timely, informed, and compassionate care with Dr. Rosaline Quinlivan, Professor of Neuromuscular Disease at University College London.